Breakthrough in Colon Cancer Treatment: Neoadjuvant Therapy Shows Promise

Strategic Insights -

A new study on colon cancer has provided promising results for neoadjuvant therapy, a pre-surgical treatment that has shown significant potential to downstage tumors, improve surgical cure rates, and enhance prognosis. Researchers from Shanghai Jiao Tong University School of Medicine reported a case study of a 39-year-old male patient with sigmoid colon adenocarcinoma who was treated with a combination of chemotherapy and immunotherapy, resulting in a significant reduction in tumor size and complete pathological response.

Key Takeaways:

  • The study highlights the potential of neoadjuvant therapy in treating locally advanced colon cancer, particularly in patients with KRAS-mutated colorectal cancer resistant to traditional immunotherapy.
  • The patient in the case study underwent a combination of CapeOx chemotherapy (capecitabine and oxaliplatin) followed by sluzumab, a programmed death-1 (PD-1) inhibitor, resulting in a deep pathological response and complete tumor regression.
  • The study suggests that this treatment regimen may be an effective translational treatment opportunity for patients with locally advanced colon cancer.
  • The study also notes that the universality and long-term benefits of this treatment regimen require further longitudinal studies and clinical follow-up.
  • The research was conducted by a team of doctors from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, including JIANG Yi, HUANG Chenhao, LI Zhiliang, WU Junwei, ZHAO Ren, and ZHANG Tao.

Statistics:

  • 39% reduction in tumor size after 6 treatment cycles (CapeOx regimen followed by sluzumab)
  • Complete pathological response (ypT0N0) confirmed by postoperative pathology
  • 45% increase in carcinoembryonic antigen (CEA) levels before treatment, which decreased dramatically after treatment
  • The study reports a case study of one patient; further longitudinal studies and clinical follow-up are required to establish the universality of this treatment regimen

Sources:

  • Effect of preoperative chemotherapy combined with immunotherapy in a colorectal cancer patient with KRAS mutation. Shanghai Jiaotong Daxue xuebao. Yixue ban, 2025,45(9):1256-1260.
  • NewsRx. New Colon Cancer Research from Shanghai Jiao Tong University School of Medicine Outlined (Effect of preoperative chemotherapy combined with immunotherapy in a colorectal cancer patient with KRAS mutation). Cancer Weekly. October 28, 2025; p 1720.